ABUS (Arbutus Biopharma) Float Percentage Of Total Shares Outstanding: 67.22% (As of Jun. 28, 2026)


ABUS Arbutus Biopharma Corp ABUS
51 GF Score
Price $4.57
GF Value $51.39
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Arbutus Biopharma Float Percentage Of Total Shares Outstanding?

Arbutus Biopharma ABUS +3.74% 51 Float Percentage Of Total Shares Outstanding is 67.22% as of Jun. 28, 2026. GuruFocus rates ABUS with a GF Score™ of 51/100 and a GF Value™ of $51.39 (Possible Value Trap). The stock has 5 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Arbutus Biopharma's float shares is 132.78 Mil. Arbutus Biopharma's total shares outstanding is 197.54 Mil. Arbutus Biopharma's float percentage of total shares outstanding is 67.22%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Arbutus Biopharma's Insider Ownership is 3.64%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Arbutus Biopharma's Institutional Ownership is 75.36%.

ABUS
51GF Score
Arbutus Biopharma Corp ABUS
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arbutus Biopharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Arbutus Biopharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=132.78/197.54
=67.22%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 67.22% mean?
Arbutus Biopharma (ABUS) has a Float Percentage Of Total Shares Outstanding of 67.22% as of Jun. 28, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Arbutus Biopharma and its competitors.
Is Arbutus Biopharma's Float Percentage Of Total Shares Outstanding too high?
Arbutus Biopharma's current Float Percentage Of Total Shares Outstanding is 67.22%. Overall, Arbutus Biopharma has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arbutus Biopharma's Float Percentage Of Total Shares Outstanding compare to SPRY and KURA?
Arbutus Biopharma's Float Percentage Of Total Shares Outstanding of 67.22% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Arbutus Biopharma and its competitors. Arbutus Biopharma's current Float Percentage Of Total Shares Outstanding is 67.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arbutus Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Arbutus Biopharma (ABUS) is currently considered Possible Value Trap. The stock's GF Value™ is $51.39, compared to a current price of $4.57 — trading 91.1% below its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 67.22%. Arbutus Biopharma's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Arbutus Biopharma (ABUS), the current Float Percentage Of Total Shares Outstanding is 67.22% as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arbutus Biopharma (ABUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arbutus Biopharma stock appears to be undervalued. The current stock price of $4.57 is trading 91.1% below its estimated GF Value™ of $51.39. GuruFocus considers Arbutus Biopharma to be Possible Value Trap.

Key valuation signals for ABUS:

  • Float Percentage Of Total Shares Outstanding: 67.22%
  • GF Value™: $51.39 vs. price of $4.57 (91.1% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the ABUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arbutus Biopharma Business Description

Other Exchanges I9DN:Germany
Address 701 Veterans Circle, Warminster, PA, USA, 18974
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
51GF Score

Get the complete analysis for ABUS

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.57
Price
$51.39
GF Value